| 14.11 Data as of May 20 |  -0.17 / -1.19%Today’s Change | 6.62 Today|||52-Week Range 14.77 | +55.05% Year-to-Date |
| NPS Pharma Incurs Narrower 1Q Loss - Analyst Blog May 14 / Zacks.com | NPS Pharmaceuticals Inc Stock Upgraded (NPSP) May 14 / TheStreet.com |
| Previous close | 14.28 |
| Today’s open | 14.28 |
| Day’s range | -- - -- |
| Volume | 866,504 |
| Average volume (3 months) | 1,937,412 |
| Market cap | $1.3B |
| Dividend yield | -- |
| Earnings growth (last year) | +51.11% |
| Earnings growth (this year) | +7.20% |
| Earnings growth (next 5 years) | +80.00% |
| Revenue growth (last year) | +28.53% |
| P/E ratio | NM |
| Price/Sales | 6.06 |
| Price/Book | -- |
| Today’s change | Today’s % change | |
|---|---|---|
| ACORAcorda Therapeutics ... | -0.78 | -2.37% |
| AKRXAkorn Inc | +0.33 | +2.28% |
| SNTSSantarus Inc | +0.19 | +0.87% |
| IPXLImpax Laboratories I... | +0.01 | +0.05% |
| Next reporting date | August 6, 2013 |
| EPS forecast (this quarter) | -$0.07 |
| Annual revenue (last year) | $130.6M |
| Annual profit (last year) | -$18.7M |
| Net profit margin | -14.34% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Francois Nader, MD, MBA |
Chief Financial Officer & Executive Vice President Luke M. Beshar, CPA |
Corporate headquarters Bedminster, New Jersey |
.
